TapImmune (NASDAQ:MRKR) had its price target reduced by equities research analysts at Piper Jaffray Companies from $10.00 to $6.00 in a research report issued to clients and investors on Wednesday, The Fly reports. The firm presently has an “overweight” rating on the stock. Piper Jaffray Companies’ price objective points to a potential upside of 104.78% from the company’s current price.
Other analysts also recently issued research reports about the company. Janney Montgomery Scott reiterated a “buy” rating on shares of TapImmune in a research report on Sunday, July 21st. ValuEngine upgraded TapImmune from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Zacks Investment Research downgraded TapImmune from a “hold” rating to a “sell” rating in a research report on Thursday, October 10th. Finally, Nomura reiterated a “buy” rating and issued a $16.00 price objective on shares of TapImmune in a research report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. TapImmune has a consensus rating of “Buy” and a consensus target price of $10.15.
Shares of MRKR traded down $0.99 during trading on Wednesday, reaching $2.93. The company’s stock had a trading volume of 1,933,000 shares, compared to its average volume of 260,618. The company has a fifty day moving average of $4.42 and a two-hundred day moving average of $5.60. The company has a quick ratio of 16.85, a current ratio of 16.85 and a debt-to-equity ratio of 0.01. TapImmune has a twelve month low of $2.79 and a twelve month high of $9.17. The company has a market cap of $182.68 million, a price-to-earnings ratio of -1.75 and a beta of 0.16.
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Recommended Story: Using other technical indicators with support levels
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.